Gyre Therapeutics (GYRE) Inventory Average (2024 - 2026)

Gyre Therapeutics (GYRE) has 3 years of Inventory Average data on file, last reported at $10.8 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $10.8 million, up 51.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.8 million (up 51.41% YoY), and the FY2025 annual result was $8.3 million, up 55.47% from the prior year.
• Inventory Average advanced to $10.8 million in Q1 2026 per GYRE's latest filing, from $9.5 million in the prior quarter.
• Over five years, Inventory Average peaked at $10.8 million in Q1 2026 and troughed at $4.6 million in Q1 2024.
• A 3-year average of $7.4 million and a median of $7.1 million in 2025 frame the typical range for Inventory Average.
• On a YoY basis, Inventory Average climbed as much as 58.3% in 2025 and fell as far as 47.45% in 2025.
• A 3-year view of Inventory Average shows it stood at $6.4 million in 2024, then soared by 49.61% to $9.5 million in 2025, then increased by 13.13% to $10.8 million in 2026.
• Business Quant data shows GYRE's Inventory Average at $10.8 million in Q1 2026, $9.5 million in Q4 2025, and $8.9 million in Q3 2025.